Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that demand was slowing and it could lose the race in the fast-growing obesity drug market.
Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...
3don MSN
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...
Wegovy may significantly reduce hospital admissions for any cause and overall length of stay, according to a new analysis of data from Novo Nordisk's phase 3 SELECT trial.
A trial, targeted at people living with obesity from Britain to Puerto Rico, is the first head-to-head comparison of the ...
Novo Nordisk is scheduled to report results for the third quarter on Wednesday. Here is what you need to know: NET PROFIT FORECAST: Net profit in the quarter is expected to rise 19% to 26.79 billion ...
Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4 mg in treating MASH and ...
Novo Nordisk A/S’s appetite-blocking shot semaglutide, sold under the brand names Ozempic and Wegovy, will probably ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback